HIV-1 latency reversal agent boosting is not limited by opioid use 1 2 Tyler Lilie<sup>1</sup>†, Jennifer Bouzy<sup>1</sup>†, Archana Asundi<sup>2</sup>, Jessica Taylor<sup>2,3</sup>, Samantha Roche<sup>2</sup>, Alex 3 Olson<sup>2</sup>, Kendyll Coxen<sup>1</sup>, Heather Corry<sup>1</sup>, Hannah Jordan<sup>1</sup>, Kiera Clayton<sup>4</sup>, Nina Lin<sup>2</sup>‡, Athe 4 Tsibris<sup>1,5</sup>‡\* 5 † These authors contributed equally to this work 6 7 ‡ These authors contributed equally to this work 8 **Affiliations:** 9 <sup>1</sup>Brigham and Women's Hospital, Boston, MA, USA. 10 <sup>2</sup>Department of Medicine, Boston University School of Medicine & Boston Medical 11 12 Center, Boston, MA USA. <sup>3</sup>Grayken Center for Addiction, Boston Medical Center, Boston, MA USA. 13 <sup>4</sup>Department of Pathology, University of Massachusetts T.H. Chan School of Medicine, 14 Worcester, MA, USA. 15 <sup>5</sup>Harvard Medical School, Boston, MA, USA. 16 \*Correspondence: atsibris@bwh.harvard.edu 17 18 **Short title:** Opioid use effects on novel HIV-1 latency reversal 19 20 21

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

**Abstract** The opioid epidemic may impact the HIV-1 reservoir and its reversal from latency in virally suppressed people with HIV (PWH). We studied forty-seven PWH and observed that lowering the concentration of HIV-1 latency reversal agents (LRA), used in combination with small molecules that do not reverse latency, synergistically increases the magnitude of HIV-1 reactivation ex vivo, regardless of opioid use. This LRA boosting, which combines a Smac mimetic or low-dose protein kinase C agonist with histone deacetylase inhibitors, can generate significantly more unspliced HIV-1 transcription than phorbol 12-myristate 13-acetate (PMA) with ionomycin (PMAi), the maximal known HIV-1 reactivator. LRA boosting associated with greater histone acetylation in CD4<sup>+</sup> T cells and modulated T cell activation-induced markers and intracellular cytokine production; Smac mimetic-based boosting was less likely to induce immune activation. We found that HIV-1 reservoirs in PWH contain unspliced and polyadenylated (polyA) virus mRNA, the ratios of which are greater in resting than total CD4<sup>+</sup> T cells and can correct to 1:1 with PMAi exposure. Latency reversal results in greater fold-change increases to HIV-1 poly(A) mRNA than unspliced message. Multiply spliced HIV-1 transcripts and virion production did not consistently increase with LRA boosting, suggesting the presence of a persistent post-transcriptional block. LRA boosting can be leveraged to probe the mechanisms of an effective cellular HIV-1 latency reversal program.

#### Introduction

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

HIV-1 proviral DNA remains integrated in CD4<sup>+</sup> T cells during suppressive antiretroviral therapy (ART) and is a barrier to cure. This virus reservoir, defined as cells that contain provirus capable of generating infectious virions, is initially seeded within days of infection before symptoms develop (1, 2), persists (3-5), decays slowly (6), and can be maintained indefinitely (7, 8). The best approach to pursue HIV eradication remains uncertain. One strategy aims to pharmacologically reactivate latent HIV transcription in the setting of suppressive ART, induce virus protein production in infected cells, and then clear the reservoir through immune-mediated mechanisms (9-11). HIV-1 latency reversal agents (LRA) have advanced into clinical trials as monotherapy but with modest results; transient increases in virus cell-associated RNA (caRNA) production may be observed with some LRA but does not translate into a decrease in reservoir size (12-22). HIV-1 latency may be characterized by transcriptional blocks that cannot be overcome by single LRA (23-26). To address these limitations, novel classes and combinations of LRA have been studied (27). Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase C agonists or second mitochondria-derived activator of caspase (Smac) mimetics, have been reported under some conditions to synergistically increase HIV-1 transcription in CD4<sup>+</sup> T cells isolated from virally suppressed participants with HIV (28-32). Generally, the sample sizes were small and evaluated LRA concentrations in the mid-nanomolar to micromolar range. The absolute amount of HIV-1 latency reversal reported with combination LRA, defined primarily as induced levels of HIV-1 caRNA, has been significantly less than that observed with the maximal HIV-1 reactivating combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin

(PMAi). A trade-off may exist between maximum synergy and maximum efficacy in combination LRA approaches (33).

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

While HIV-1 is generally accepted to be transcriptionally silent during suppressive ART, this latency may not be absolute. Studies demonstrate that short promoter proximal transcripts of less than 60 nucleotides may be generated in the absence of the HIV-1 trans-activator of transcription protein, Tat (34, 35). More recently, resting CD4<sup>+</sup> T cells isolated from PWH were found to contain transcripts extending beyond the transcriptional pausing site, a minority of which may be full-length or spliced and polyadenylated (36). Total CD4<sup>+</sup> T cells isolated from PWH may contain approximately sevenfold more proximal HIV-1 transcripts, of at least 185 nucleotides in length, than polyadenylated virus mRNA (23). HIV-1 cell-associated RNA is readily detectable in the blood and tissue of PWH on virologically suppressive ART (37-40). People with HIV may be exposed to opioids, whether prescribed for chronic pain (41), prescribed for opioid use disorder (42), or injected as heroin (43). The pharmacology of opioids associated with substance use disorders may differ from opioid medications used to treat chronic pain. The µ opioid agonists, e.g. heroin, fentanyl, morphine, and methadone, can block IL-2 mRNA and protein production in activated T cells through inhibition of AP-1, NFAT, and NFκB activation, transcription factors known to be positive regulators of HIV transcription initiation (44-46). The effects of buprenorphine, a partial  $\mu$  opioid agonist and  $\kappa$  and  $\delta$  opioid antagonist commonly used in the treatment of opioid use disorder, on HIV-1 latency and its reversal have not been explored. A recent finding suggested that people with HIV who use opioids may have diminished responses to latency reversal mediated by T cell receptor (TCR) agonism (47).

To investigate the mechanisms that control HIV-1 latency reversal during opioid use, we enrolled a cohort of thirty-six treated, virologically suppressed participants with HIV. We originally hypothesized that opioid use would limit HIV-1 latency reversal and vary as a function of opioid use type. We tested LRA combinations at concentrations lower than those typically assessed and identified the phenomenon of LRA boosting: synergistic HIV-1 transcriptional reactivation with small molecules that do not reverse latency as single agents. We corroborated these findings in an additional eleven participants from a separate cohort and identified key associations between potent LRA boosting, increases in histone acetylation, modulation of T cell phenotype and function, and downstream blocks to virion production. While benchmarking LRA boosting, we observed that HIV-1 transcription during treated infection may be greater than previously appreciated and varies by CD4<sup>+</sup> T cell phenotype. Importantly, we find that opioid use did not limit the magnitude or mechanisms of LRA boosting.

#### **Results**

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

# Opioid use does not affect HIV-1 reservoir size

We enrolled the Opioids, HIV, and Translation (OPHION) cohort from a single academic center of thirty-six virally suppressed participants with HIV who used, or did not use, opioids in a 2:1 ratio. Participants had a median age of 59 years, included one-third women, and were approximately 30% white (**Table 1**). The median duration of ART was 12 years with a median duration of undetectable plasma HIV-1 RNA levels of over six years. Participant characteristics were further defined by type of opioid use (**Suppl. Table 1**) and validated by urine toxicology and self-reported substance use questionnaires (Suppl. Fig. 1). To reflect the range of opioid use encountered in clinical practice, this cohort comprised participants who actively injected opioids (n=4), used methadone (n=4) or suboxone (n=12) as medication for opioid use disorder, or took opioids for chronic pain (n=4). Amphetamine and barbiturate use were not detected. All active injection opioid users had confirmatory urine toxicology screens positive for fentanyl (n=2 of 4, range 62 - >500 ng/mL) and/or norfentanyl (n=4 of 4 participants, range 46 - >500 ng/mL) and reported a median of 6 days of injection opioid use in the preceding 30 days (IQR 4-16 days) with a median of 7 days since the most recent use (IQR 4-14 days). All participants in the methadone, buprenorphine, and prescription opioid subgroups had urine toxicology positive for that substance. To assess markers of HIV-1 persistence, we quantified total HIV-1 DNA and caRNA in PBMC and evaluated intact proviral reservoir size (Fig. 1). Total HIV-1 DNA levels were statistically similar between opioid and non-opioid groups, 2.36 vs 2.38 log<sub>10</sub> copies/10<sup>6</sup> PBMC, respectively, as were HIV-1 caRNA levels, 2.45 vs 2.52 log<sub>10</sub> copies/10<sup>6</sup> PBMC (**Fig. 1a**). Levels of intact provirus DNA were also similar between groups, 2.00 vs 1.82 log<sub>10</sub> copies/10<sup>6</sup>

# **Table 1. OPHION Participant Characteristics**

	Cohort		
Characteristic	Non-Opioid	Opioid	Total*
Participants, N	12	24	36
Age			
Median (IQR <sup>†</sup> )	56 (50-61)	61 (55-65)	59 (54-65)
Sex			
Male N (%)	7 (58%)	17 (71%)	24 (67%)
Race			
Black N (%)	10 (83%)	6 (25%)	16 (44%)
White N (%)	2 (17%)	9 (38%)	11 (31%)
Hispanic/Latino** N (%)	0	2 (8%)	2 (6%)
American Indian N (%)	0	1 (4%)	1 (3%)
Declined/NA	0	6 (25%)	6 (17%)
Ethnicity			
Non-Hispanic N (%)	11 (92%)	13 (54%)	24 (67%)
Hispanic N (%)	1 (8%)	11 (46%)	12 (33%)
Duration of ART (months)			
Median (IQR)	162 (106-204)	136 (91-173)	144 (97-179)
Duration of viral suppression (months)			
Median (IQR)	69.5 (38-91)	79 (51-94)	75 (44-93)

<sup>\*</sup>Percentage totals may not add up to 100 due to rounding. †IQR, interquartile range. \*\*Participants may identify as Hispanic/Latino either in response to a question about their race, or a follow-up question on ethnicity. Participants who reported Hispanic ethnicity identified their race as either "White" or "Declined/Not Available."

PBMC. To better define the intact proviral DNA reservoir, we characterized 5' and 3' HIV-1 deletions across cohorts and opioid use subgroups (**Fig. 1b-c**). Similar proportions of intact 5' and 3' genetic regions were observed, irrespective of opioid use. The ratios of proviruses containing an intact 5' region and a defective (hypermutated) or deleted 3' region in HIV-1 *env* were statistically similar. An exploratory analysis demonstrated a greater proportion of total genomes were intact in active injection opioid users, although this result was not significant when adjusted for multiple comparisons (**Fig. 1d**).

# LRA boosting markedly increases HIV-1 transcription

To determine the effects of opioid use on HIV-1 latency reversal *ex vivo*, we isolated PBMC from thirty-six participants enrolled in the OPHION cohort and tested a panel of ten LRA conditions (**Fig. 2**). The histone deacetylase inhibitors (HDACi) romidepsin (RMD) and panobinostat (PNB) were used at the lowest concentrations most commonly reported in the literature and the protein kinase C agonist bryostatin was tested at 1nM, one-tenth the most commonly reported concentration. In single LRA conditions, we observed a 2.7-fold activation of HIV-1 caRNA transcription, relative to an untreated DMSO-containing control, with anti-CD3/anti-CD28 (αCD3/αCD28) beads, a T cell receptor (TCR) agonist (**Fig. 2a**). This magnitude of TCR agonism-induced latency reversal is consistent with prior studies (23, 48-52). Statistically greater reactivation was observed with RMD (3.8-fold increase) when compared to PNB (2.6-fold increase) (**Suppl File 1**). Low-dose bryostatin minimally increased unspliced HIV-1 caRNA levels (1.2-fold increase), but the Smac mimetic AZD5582 (AZD), at a standard concentration (53), did not (0.9-fold increase, 95% CI [0.8, 1.1]).

We next assessed LRA in combination. Incubation of PBMC with HDACi and either AZD or low-dose bryostatin potentiated HIV-1 latency reversal. AZD in combination with PNB or RMD increased HIV-1 caRNA levels 8.1-fold and 9.1-fold, respectively. Low-dose bryostatin with PNB increased HIV-1 caRNA 10.6-fold, whereas the greatest fold-induction of HIV-1 caRNA was observed with the combination of low-dose bryostatin and RMD (13.2-fold). Statistically greater HIV-1 RNA induction was observed with the LRA boosting combinations relative to HDACi monotherapy and TCR agonism, when corrected for multiple comparisons. We compared LRA response as a function of opioid use (Fig. 2b), sex (Fig. 2c), race (Fig. 2d), and ethnicity (Suppl. Fig. 2a) and observed no statistically significant differences in the fold-changes of HIV-1 caRNA induction across these groups. In an exploratory analysis, the fold-change in HIV-1 caRNA varied by opioid use subgroup in response to T cell receptor agonism (Suppl Fig 2b). Statistically significantly greater reactivation with αCD3/αCD28 beads was observed in the suboxone sub-group when compared to active injection opioid users, the group with the smallest fold-change in TCR agonism-induced HIV-1 caRNA levels.

## LRA boosting modulates T cell activation and cytokine production

To understand whether LRA boosting activates CD4<sup>+</sup> T cells, we assessed the upregulation of surface activation-induced markers (AIM) (54). We leveraged dual-marker AIM assays (**Suppl. Fig. 3, Fig. 3a**), originally developed to detect T cell antigen responsiveness, to quantify cellular activation that occurs with LRA exposure, outside the context of peptide-specific recognition. Using TCR agonism as a positive control, responses were detected in 49%, 32%, and 42% of CD4<sup>+</sup> T cells in the OX40/PDL1, OX40/CD25, and CD69/CD40L AIM assays, respectively (**Fig. 3b**). Low-dose bryostatin significantly upregulated surface expression to more

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

modest levels in all three AIM assays, relative to an untreated control condition. Bryostatin induced OX40/PDL1 surface expression in 5.2% of CD4<sup>+</sup> T cells, levels of induction that did not significantly change when used in combination with RMD (5.4%) or PNB (3.5%). Bryostatin monotherapy induced expression in 6.9% and 2.6% of CD4s in the OX40/CD25 and CD69/CD40L AIM assays, respectively. In these two assays, the combination of RMD or PNB with low-dose bryostatin significantly reduced activation-induced markers, relative to bryostatin alone, and in some cases to control (untreated) levels; these findings did not differ by opioid use (Suppl. Fig. 4a-c). The remainder of the LRA panel and their combinations did not upregulate surface expression in any AIM assay. We observed a more pronounced upregulation in isolated CD69 expression, an early activation marker, in response to LRA. Approximately 0.5% of untreated CD4<sup>+</sup> T cells expressed CD69 after 18 hours in culture (**Fig. 3c**). The proportion of cells expressing surface CD69 significantly increased to similar levels with TCR agonism (68.5%) and low-dose bryostatin (72.9%). Whereas AZD5582 (1.0%), RMD (4.7%), and PNB (5.4%) modestly increased CD69 levels, combinations of these small molecules led to synergistic effects. Significantly greater induction of CD69 expression was observed when RMD or PNB was combined with bryostatin or AZD5582; a bryostatin combination induced more CD69 than an HDACi plus AZD5582. CD69 levels were statistically similar when comparing TCR agonism, bryostatin alone, and bryostatin in combination with either HDACi (**Suppl. Fig. 4d**). To further probe LRA effects on T cell activation, we stained CD4<sup>+</sup> (CD4s) and CD8<sup>+</sup> T cells (CD8s) for intracellular cytokine production (Fig. 3d-e). Whereas cytokine assessments in T lymphocytes most commonly include IL-2 and IFN-γ, we additional quantified intracellular TNF-α by flow cytometry. We observed a cytokine production hierarchy in CD4s, where the

levels were TNF- $\alpha > IL-2 > IFN-\gamma$ , and in CD8s, where TNF- $\alpha > IFN-\gamma > IL-2$ . In response to TCR agonism, significantly more CD4s produce TNF-α (30.4%) than IL-2 (14.3%) or IFN-γ (6.0%), and significantly more IL-2 than IFN-γ (**Suppl. Fig. 4e**). We identified a different hierarchy in CD8<sup>+</sup> T cells (CD8s), where the proportion of cells producing TNF-α remained greatest (17.5%) but significantly more IFN-y (9.0%) was produced compared to IL-2 (4.3%). Whereas HDACi monotherapy did not increase the proportion of CD4s or CD8s producing cytokines compared to an untreated control, low-dose bryostatin alone or in combination with HDACi significantly increased production of TNF-α and, to a smaller magnitude, IFN-γ in CD4s. Significantly more CD4s produced TNF-α than IFN-γ in response to RMD + bryostatin (4.5% versus 1.3%) and PNB + bryostatin (4.2% versus 1.7%) (**Suppl. File 1**). In CD8s, lowdose bryostatin significantly increased production of TNF- $\alpha$  (2.8%) and IFN- $\gamma$  (1.5%). The proportions of CD8s that produced TNF-α and IFN-γ when exposed to the combinations of RMD + bryostatin (3.4% versus 4.7%) and PNB + bryostatin (4.1% versus 4.6%) were similar and were statistically similar to bryostatin alone. IL-2 production did not increase above 0.1% of CD4s or CD8s for any LRA, or combination, we tested.

# LRA boosting increases histone acetylation

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

To investigate the mechanism(s) of LRA boosting, we next assessed histone acetylation. The proportions of acetylated histone H3<sup>+</sup> live CD4s were similar between untreated cells (19.7%) and cells exposed to RMD (21.8%), PNB (21.7%), or AZD (19.8%) and significantly increased after single-LRA exposure to αCD3/αCD28 beads (35.5%) and low-dose bryostatin (29.2%) (**Fig. 4a**). Low-dose bryostatin in combination with either RMD (36.8%) or PNB (37.5%) significantly increased the proportions of CD4s contained acetylated histone H3.

Interestingly, statistically significant increases in the proportions of acetylated histone H3<sup>+</sup> live CD4s were also observed when combining LRA which individually did not affect these percentages, specifically RMD + AZD (30.0%) and PNB + AZD (29.8%). These results did not differ by opioid use (**Suppl. Fig 5a**).

Levels of acetylated histone H3, measured by median fluorescence intensity (MFI), were similar in untreated live CD4s and in cells cultured with αCD3/αCD28 beads, low-dose bryostatin, or AZD (**Fig. 4b**). Significant 3.4-fold and 3.3-fold increases in acetyl histone MFI were observed for RMD and PNB, respectively. AZD in combination with RMD or PNB further increased MFI by 6.1- fold and 5.7-fold, respectively. Absolute increases in MFI were observed for low-dose bryostatin in combination with RMD or PNB but did not retain significance after correction for multiple comparisons. These results did not differ by opioid use (**Suppl. Fig 5b**). We observed no association between acetylated histone H3 MFI and fold-change in HIV-1 RNA levels for HDACi monotherapy or for HDACi in combination with AZD (**Fig 4c-d**). A statistically significant weak association between the proportion of acetyl histone H3<sup>+</sup> CD4s and fold-change in HIV-1 RNA levels was detected for HDACi in combination with bryostatin (**Fig 4e**).

## LRA boosting does not consistently induce virion production

To extend our analyses from the OPHION cohort, we next studied an additional eleven participants with HIV who did not use opioids, enrolled in the HEAL cohort, for whom leukapheresis samples were available (**Supplementary Table 2**). We compared LRA boosting responses in PBMC to the most potent known HIV-1 LRA, PMA in combination with ionomycin (PMAi). Significant fold-change increases in HIV-1 transcription were observed with

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

combinations of low-dose bryostatin with RMD (8.3-fold) or PNB (8.0-fold), when compared to RMD alone (3.4-fold), PNB alone (3.1-fold), or PMAi (1.6-fold) (Fig. 5a). In separate experiments, we observed statistically similar HIV-1 transcription with an HDACi in combination with AZD, relative to PMAi (Fig 5b). No significant increases in HIV-1 transcription were observed in PBMC experiments with low-dose bryostatin (1.0-fold, 95% CI 0.9, 1.1) or AZD (1.2-fold, 95% CI 0.6, 1.9). Similar magnitudes of HIV-1 transcriptional reactivation were seen with HDACi monotherapy, low-dose bryostatin, and AZD monotherapy across the OPHION and HEAL cohorts we studied. We evaluated human reference gene transcription per million PBMC during LRA treatment and observed decreases with HDACi exposure, increases with PMAi, and variable changes with bryostatin (**Suppl. Fig. 6**) (37, 55). To assess the magnitude of HIV-1 latency reversal as a function of cell type, we next performed parallel experiments in PBMC and total CD4<sup>+</sup> T cells (**Fig. 5c**). While CD4<sup>+</sup> T cells are the only established HIV-1 reservoir in PBMC, we performed this comparison across cell types to increase experimental rigor. Levels of HIV-1 caRNA were, on average, 4.3-fold higher (range 3.2 - 6.0) across experimental conditions performed in CD4<sup>+</sup> T cells, when compared to PBMC, and varied by 1.6  $\log_{10}$  (PBMC) and 1.8  $\log_{10}$  (CD4) across participant samples in the absence of LRA exposure. To control for absolute caRNA differences, we determined foldchanges in LRA response and observed statistically significant increases in HIV-1 caRNA with low-dose bryostatin in combination with RMD or PNB, when compared to PMAi, in both PBMC and CD4s (Fig. 5d). To explore the variance in LRA response, we compiled per-participant biological replicate measurements (Suppl. Fig. 7a). Supernatant HIV-1 RNA levels increased after 24hr incubation of PBMC with PMAi (19 copies/mL, 95% CI [10, 32]) and the combinations of RMD plus bryostatin (27 copies/mL, 95% CI [11, 34]) or AZD (31 copies/mL,

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

95% CI [14, 43]), and PNB plus bryostatin (35 copies/mL, 95% CI [19, 60]) or AZD (12 copies/mL, 95% CI [8.1, 26]), when compared to untreated PBMC (3.0 copies/mL, 95% CI [2.2, 6.9]), but these results were not statistically significant after correction for multiple comparisons (Fig. 5e). This virion production response was dichotomized by participant. For each LRA condition, PBMC samples from at least 5 of 10 participants showed no increases in HIV-1 RNA levels over control; these were most commonly the same participants. Additionally, no significant increases in LRA-induced virion production in isolated CD4<sup>+</sup> T cell cultures were observed. Greater virion production in untreated CD4s and greater absolute magnitudes of LRAassociated supernatant viremia in CD4s were noted, relative to PBMC, but these increases were seen in only a subset of participants. To define this post-transcriptional block more precisely, we quantified the frequency of CD4s with inducible multiply spliced HIV-1 RNA transcripts (Fig. 5f) (56). No significant increases in the frequency of cells that contain HIV-1 tat/rev transcripts were observed with RMD in combination with bryostatin at either 1nM or 10nM concentrations. In a post-hoc analysis, we combined datasets from OPHION and HEAL participants, including LRA conditions common to both sets of experiments, and observed statistically significant increases in HIV-1 unspliced RNA transcription with all LRA boosting combinations (Fig. 5g, **Suppl. Fig 7b**). The variance in LRA response, defined by the interquartile range, increased as the magnitude of fold change in HIV-1 caRNA increased. Effective latency reversal normalizes unspliced:polyadenylated HIV-1 mRNA ratios We observed lower PMAi-associated fold-changes in HIV-1 caRNA levels with our unspliced HIV-1 RNA qPCR assay when compared to prior studies that quantified poly-adenylated (poly(A)) HIV-1 mRNA (28, 32). These assays differ methodologically and so we directly

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

compared them and assessed the effects of primer location, CD4<sup>+</sup> T cell phenotype, and CD4<sup>+</sup> T cells density on HIV-1 caRNA quantifications (Fig. 6a). In response to a 24-hour PMAi exposure, levels of HIV-1 unspliced caRNA increased 4.3 – 8.6-fold. These levels did not significantly differ between resting (rCD4, CD25 CD69 HLA-DR and total CD4 T cell (tCD4) stimulations, nor when CD4<sup>+</sup> T cells were cultured at densities of 5x10<sup>6</sup> or 1x10<sup>6</sup> cells/mL. Poly(A) HIV-1 caRNA levels increased 32-34-fold with the same PMAi stimulation and were statistically significantly greater than unspliced HIV-1 caRNA fold-changes for each input CD4<sup>+</sup> T cell phenotype or cell density. While PMAi-induced fold-changes in HIV-1 RNA were similar between rCD4 and tCD4, we observed differences in the amounts of unspliced and polyadenylated message present in these untreated cell populations. In the absence of LRA treatment, significantly greater ratios of unspliced to poly(A) HIV-1 caRNA were seen in rCD4 (10.6-13.3), relative to tCD4 (2.8-3.5) (**Fig 6b**). The differences in these ratios were driven by differences in HIV-1 poly(A) transcript levels. While untreated rCD4 and tCD4 at 5 million or 1 million cells/mL contained similar absolute levels of unspliced HIV-1 caRNA transcripts (p=0.98 for each), untreated tCD4 demonstrated statistically greater copy numbers of HIV-1 poly(A) mRNA per million CD4s (p<0.005 at 5m cells/mL, p<0.001 at 1mL cells/mL, Freidman test (ANOVA) with Dunn's correction for multiple comparisons; **Suppl File 1**). PMAi stimulation normalized unspliced:poly(A) ratios to 1.7-2.4 in rCD4 and 0.8-1.0 in tCD4s (**Fig 6c**, d). Significantly lower ratios of unspliced:poly(A) HIV-1 RNA were observed in reactivated tCD4, when compared to rCD4 (**Fig. 6e**).

## **Discussion**

An approach to cure HIV infection should be equally effective for all people. Here we explored how opioid use may affect our ability to reverse HIV-1 latency. Opioid use is complex and can be accompanied by comorbidities, such as immune activation with injection drug use (57, 58), that may impact the HIV-1 reservoir and its persistence (37, 59-62). Here we found no effects of opioid use by indication, type, or pharmacology on markers of HIV-1 persistence. In the setting of persistently suppressed viremia, opioid use was less likely to modulate virus reservoir size, findings that agree with recent studies of injection heroin use (47, 63). Overall, participants were matched on the duration of ART and virus suppression, key variables that have been associated with HIV-1 reservoir size (64), and our urine toxicology results were consistent with the participants' ascribed opioid use group.

We used samples from opioid users to identify the phenomenon of LRA boosting: improving the potency of HDACi beyond that of PMA-ionomycin by combining with a 2<sup>nd</sup> drug that does not, by itself, re-activate HIV-1 transcription. This boosting occurred at lower LRA concentrations, here at least half the RMD, 1/10<sup>th</sup> the bryostatin, and 1/100th the Smac mimetic concentrations used in prior combination studies (28-31). Synergistic latency reversal effects of low-dose bryostatin (1nM) and romidepsin was previously identified in samples from four participants with HIV (28). Here we leveraged samples from forty-seven participants to confirm those findings, extend the observation to HDACi in combination with low-dose bryostatin more generally, and to LRA boosting with a Smac mimetic. A recent study identified that injection opioid use was associated with a lack of ex vivo HIV-1 activation to TCR agonism (47). and our findings in the subgroup of active injection opioid users agree with this. However, this observation did not extend to other types of opioid use, e.g. suboxone use. Additional studies are

needed to corroborate these findings in a larger sample size and investigate why HIV-1 latency reversal by TCR agonism may be particularly affected by injection opioids.

While AZD5582 has been reported to induce virus transcription, we observed no HIV-1 latency reversal activity when used as a single agent in PBMC isolated from the 47 participants we tested. AZD5582 monotherapy has been assessed for human ex vivo HIV-1 latency reversal activity in four prior studies, using the endpoints of a quantitative virus outgrowth assay, HIV-1 cell-associated RNA levels, and HIV-1 p24 production. In these studies, QVOA and p24 responses were not observed in the majority of participants, HIV-1 gag caRNA increases were approximately 2-fold, and the statistical significance of the results was less clear (53, 65, 66). Our findings agree more with a recent study that assessed AZD5582 monotherapy and did not identify HIV-1 LRA activity (32).

Our relatively large sample size, for this field, allowed us to determine that LRA boosting was less likely to be affected by sex, race, or ethnicity. We do note, however, that non-opioid participants in both our OPHION and HEAL cohorts were more likely to be black, whereas participants who used opioids were a more racially and ethnically mixed population. The use of two HDACi in our panel of ten LRA conditions increased the generalizability of the findings we observed with this drug class. Similar magnitudes of boosting were observed with RMD and PNB and suggests that class I histone deacetylase inhibition may be more relevant to this phenomenon (67, 68). HDACi-induced changes in acetylated histone (AcH) H3 and/or H4 are nearly exclusively reported in the literature as changes in MFI (13, 16-19, 69-72), not as a function of the percent AcH-positive cells (16). To increase transparency, we report histone acetylation changes both as the proportion of AcH-positive cells and by MFI; the 3-4-fold MFI increases we report with RMD and PNB are consistent with prior literature. LRA boosting

correlated with increased histone H3 acetylation in CD4<sup>+</sup> T cells but AZD-associated boosting did not recruit additional CD4s with acetylated histone H3. HDACi monotherapy also did not increase the proportions of acetylated histone H3-positive CD4s and the amount of acetylated histone H3 per cell did not meaningfully correlate with the induction of HIV-1 transcription. It remains unclear if histone acetylation is correlative or causative to virus reactivation. In the context of cellular genes, histone acetylation is not an immediate driver of the transcriptional changes observed with HDACi (73). Similar magnitudes of HIV-1 reactivation were observed with low-dose bryostatin and AZD5582-mediated HDACi boosting and could share common mechanisms. Bryostatin and AZD5582 can activate canonical and non-canonical NF-κB pathways, respectively, and the overlap in signaling with LRA boosting requires further definition. A recent study performed an AZD5582-stimulated CRISPR screen and identified HDAC2 as a potential synergistic drug target (32).

We identify that HIV-1 latency during treated virologically suppressed infection in PWH is best described a period of inefficient, but not absent, virus mRNA production in blood. Real-time PCR assays that quantify HIV-1 persistence markers are not necessarily standardized across research groups; the fold-change in HIV-1 unspliced caRNA levels that we observed with PMA-ionomycin stimulation were an order of magnitude lower than some prior studies which quantified polyadenylated HIV-1 mRNA (28, 32). Our findings suggest this is not a result of assay technical performance. Rather, qPCR assays of HIV-1 unspliced and poly(A) caRNA levels may capture distinct biology, as a function of CD4<sup>+</sup> T cell phenotype. First, we identified tCD4 contain more polyadenylated HIV-1 message than rCD4 in PWH. Second, PMAi stimulation has more pronounced effects on the induction of HIV-1 poly(A) mRNA levels, relative to unspliced RNA, and explains the discrepancy in PMAi-induced HIV-1 caRNA fold-

changes between our study and others. Third, PMAi stimulation increases the levels of both HIV-1 unspliced and poly(A) and, in doing so, normalizes their ratios; this normalization is greater in tCD4. Lastly, we identify that during treated virologically suppressed infection, HIV-1 transcription generates unspliced transcripts of at least 350 nucleotides in length. We note this is distal to where RNA polymerase II promoter-proximal pausing typically occurs (74). The efficiency of HIV-1 transcription is therefore reduced during ART, but not extinguished. We speculate that while the HIV-1 long terminal repeat (LTR) can recruit RNA polymerase II under these circumstances, the transcription elongation complex may be missing virus and/or host factors required to maximize virus mRNA production and processing.

LRA boosting, and their individual components, can have off-target effects. We used cell surface and intracellular assessments of immune activation to investigate whether LRA boosting can be uncoupled from immune activation. Whereas CD69 surface expression has been proposed as a biomarker of latency reversal potency in the context of PKC agonists, we found no correlation between CD69 upregulation and the magnitude of latency reversal (75, 76). We identified less induction of CD69 expression with RMD monotherapy than a prior study, despite similar staining and gating strategies (77). While low-dose bryostatin was sufficient to increase surface activation-induced markers and increase cytokine production in CD4<sup>+</sup> and CD8<sup>+</sup> T cells, albeit to relatively low levels, the increased HIV-1 reactivation seen with LRA boosting did not increase surface AIM and in some cases reduced it – specifically by adding an HDACi to bryostatin. However, intracellular cytokine production increased modestly with these same combinations and suggests that AIM assays and ICS staining provide complementary information in the assessment of investigational LRA. Our findings suggest that future investigations into LRA-indued cytokine production should include TNF-α quantifications,

whose levels are more likely to increase than either of the more commonly assessed IL-2 and IFN-γ. In contrast, LRA boosting with AZD5582 resulted in relatively lower surface levels of CD69 and no induction of surface activation markers or cytokine production in T cells. Our results extend previous findings on the effects of combination LRA on CD8<sup>+</sup> T lymphocytes to CD4<sup>+</sup> T cells (78) and suggest that cytokine assessments of IL-2 production in CD4<sup>+</sup> T cells provide the least yield in LRA evaluations. We conclude that LRA boosting approaches can affect the immune system differently and may work through different mechanisms. An LRA boosting approach that minimizes immune modulatory effects may be more appealing as an investigational intervention.

The variance in HIV-1 LRA responsiveness we document, across participants and between replicates, has implications for future studies. Small studies may be limited in their capacity to accurately quantify this variability, which increases with LRA potency and has been observed in other in vitro and ex vivo work (79-81). We speculate this variability may relate to heterogeneity in the HIV-1 reservoir, less so in the absolute amounts of provirus that may be found in a given PBMC aliquot and more so to the capacity of a given set of proviruses, in their unique intracellular environments, to support the reactivation of virus transcription. Assessments of LRA activity should prioritize larger sample sizes and more than one biological replicate per participant. We found that normalization of HIV-1 transcription to host gene transcription may introduce additional variability. Despite HIV-1 re-activation that was superior to PMA-ionomycin, multiply spliced HIV-1 transcription and virion production did not significantly increase with RMD in combination with low-dose bryostatin. Blocks to HIV-1 splicing are increasingly recognized, and here we extend those findings to novel LRA boosting combinations (23-25, 82-84). PMAi did not induce supernatant viremia, after a 24-hour incubation, in all

participants; this heterogeneity has been previously reported (85). In CD4<sup>+</sup> T cell samples from a subset of participants, however, we did observe detectable supernatant viremia but not increases in the frequency of HIV-1 msRNA with the LRA boosting combination of romidepsin and low-dose bryostatin. It is possible that if an RNA splicing block limits LRA boosting-associated virion production, it may not be absolute. Our study did not evaluate alternative possibilities that virion production without significant HIV-1 msRNA increases may be due to virion production kinetics, i.e. msRNA may be translated and degraded, may be due to the variance in LRA response we document across experimental replicates, or may be due to assay technical differences. Future work should focus on the post-transcriptional mechanisms of HIV-1 RNA processing, and inter-patient differences in LRA responsiveness.

To standardize language, the term HIV-1 "latency reversal" may require more precise wording. Latency reversal can refer to the reactivation of virus unspliced or poly(A) mRNA transcription but can also be interpreted to mean the reversal of latency that results in viral particle production. While some prior studies have identified HDACi-induced HIV-1 virion production *ex vivo*, this required HDACi exposures over 6-14 days, at times in combination with CD8 depletion or other LRA conditions that are more difficult to translate into investigational strategies (70, 77, 79, 86).

Our study has limitations. Prior and current injection opioid use limits the peripheral blood draw volumes we could obtain; this required us to prioritize the experiments we performed with a given sample. The statistical significance of LRA boosting with AZD5582-containing regimens was not replicated in our HEAL cohort samples and it is unclear if this relates to the variability in LRA response as sample size decreases or to unrecognized differences between our cohort's participants. We observed variance across clinical cohorts in the magnitude of LRA

boosting responses to AZD5582 in combination with HDACi. While the sample sizes for these experiments differ (n=36 vs n=9) and, in aggregate, the HIV-1 caRNA fold-change effects are clear, we cannot rule out that smaller sample sizes and/or unrecognized differences between our cohort's participants may impact the significance and the magnitude of latency reversal with some LRA boosting combinations. Additional mechanisms may explain how LRA boosting increases virus transcription; bryostatin may exert its HIV-1 latency reversal effects independently of PKC agonism (87). The use of HIV-1 LRA at sub-maximal doses and in combination with small molecules that do not increase virus transcription, ex vivo, expands our understanding of how virus latency may be reversed. Follow-on studies should delineate the precise mechanisms required for efficient virus RNA processing and virion production during HIV-1 latency reversal.

## **Figure Legends**

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

Figure 1. HIV-1 reservoir size and intactness during opioid use. Quantifications were performed on participants who used (n=24) or did not use (n=12) opioids. (a) HIV-1 persistence measures in participants with (blue circles) and without (yellow circles) opioid use are shown. Statistical significance was assessed with Wilcoxon signed-rank tests. Data are displayed on a logarithmic y-axis scale; DNA and RNA was extracted from 5 million PBMC. Intact DNA was quantified with the IPDA assay. Mean values ± standard errors of the mean (SEM) are shown. (b) 5' and 3' genomic deletions as a function of opioid use, mean values  $\pm$  95% CIs are displayed, (c) Opioid subgroup analysis. The reservoir size of intact, 5' deleted, and 3' deleted or hypermutated regions are shown. (d) The proportion of intact genomes as a function of DNA copies and opioid use subgroup; Kruskal-Wallis testing adjusting for multiple comparisons was not significant. Cohort 1, injection opioid use; cohort 2, prescribed oral opioids for pain; cohort 3, methadone; cohort 4, suboxone; cohort 5, no opioid use. Figure 2. HIV-1 latency reversal in OPHION participants. HIV-1 caRNA levels were quantified after 24-hour incubations, in the presence of tenofovir 2 µM and raltegravir 2 µM, using 5 million PBMC and compared to a no-drug DMSO-containing condition. Mean values and the 95% CIs are shown. (a) Combined data showing LRA responses in thirty-six total participants with (blue circles) or without (yellow circles) opioid use. Data from (a) was dichotomized by (b) opioid use, (c) sex (light purple circles, male; light grey circles, female), and (d) race (light green circles, Black and American Indian; dark green circles, white). Means and SEM are shown. Dotted horizontal line denotes a fold-change of 1. \*p<0.05, \*\* p<0.01, \*\*\* p<0.001, and \*\*\*\*

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

p<0.0001 for LRA combinations, corrected for multiple comparisons. αCD3/αCD28, anti-CD3 anti-CD28 superparamagnetic beads; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM. **Figure 3.** Immune activation and cytokine induction during *ex vivo* LRA boosting. (a) Example plots of OX40<sup>+</sup>PD-L1<sup>+</sup>, OX40<sup>+</sup>CD25<sup>+</sup>, and CD69<sup>+</sup>CD40L<sup>+</sup> expression from gated live CD4<sup>+</sup> T cells in PBMC samples incubated with DMSO control or an αCD3/αCD28 bead positive control for 18 hours, (b) Violin plots of surface activation-induced marker (AIM) response as a function of LRA. Results across three highly sensitive AIM assays for OPHION participants' samples (n=36) are shown for comparison, (c) Quantification of LRA-induced surface CD69 expression in live total CD4<sup>+</sup> T cells (n=36). Intracellular production of the cytokines TNF-α, IFN-γ, and IL-2 during LRA exposure in (d) live CD4<sup>+</sup> and (e) CD8<sup>+</sup> T cells (n=36). Violin plot median values are indicated by a solid black line; quartiles are shown with a dotted line. LRA conditions without visible bars represent values < 0.1% of cells. \*p<0.05, \*\*\* p<0.001, and \*\*\*\* p<0.0001 for LRA combinations, corrected for multiple comparisons. RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM. Figure 4. LRA boosting increases histone acetylation. (a) Violin plots showing the proportion of gated live total CD4<sup>+</sup> T cells with acetylated histone H3, assessed by flow cytometry, (b) Violin plot of mean fluorescence intensity (MFI) of acetylated histone H3 per live CD4<sup>+</sup> T cell. Scatter plots of acetylated histone H3 levels per CD4 as a function of HIV-1 transcription in response to RMD and PNB monotherapy (c), LRA boosting with HDACi and AZD5582 (d), and HDACi in combination with low-dose bryostatin (e) are shown. Acetylated histone levels and HIV-1

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

reactivation with the combinations of HDACi and bryostatin were moderately positively correlated (r=.25, p=.04). Violin plot median values are indicated by a solid black line; quartiles are shown with a dotted line. **Figure 5.** Comparative analysis of LRA boosting effects in PBMC and CD4<sup>+</sup> T cells. Leukapheresis samples from HEAL cohort participants (n=11) were used to assess HIV-1 unspliced caRNA levels during (a) low-dose bryostatin-based and (b) AZD5582-based LRA boosting combinations in PBMC, when compared to PMA-ionomycin. Data are presented as means  $\pm$  SEM. Circle color is used to denote a given HEAL participant across Figure panels. (c) Absolute HIV-1 unspliced caRNA levels in parallel PBMC and CD4<sup>+</sup> T cell LRA exposures. PBMC and CD4 results are separated by a vertical dotted line. (d) Representation of the data in (c) as fold-change in HIV-1 caRNA levels. (e) Corresponding HIV-1 RNA levels from culture supernatants. (f) Multiply spliced HIV-1 RNA levels as determined in a modified TILDA assay, comparing RMD-bryostatin combinations at two bryostatin concentrations to PMA-ionomycin. (g) Combined OPHION and HEAL participant results (n=47) that summarize PBMC LRA boosting responses, for LRA conditions common to both datasets. Results from OPHION participant samples, carried over from Fig. 2a, are shown in grey circles. HEAL participant results are shown in color. \*p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001, corrected for multiple comparisons. NDC, no-drug control, contains 0.2% DMSO; PMAi, PMA with ionomycin; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM.

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

Figure 6. Latency reversal polyadenylates pre-existing unspliced HIV-1 mRNA (a) Resting and total CD4<sup>+</sup> T cell HIV-1 transcriptional profiles during PMA-ionomycin exposure. HEAL participant samples (n=10) were used to assess the effects of CD4<sup>+</sup> T cell phenotype and cell culture density on fold-changes in HIV-1 unspliced and poly(A) transcripts during latency reversal with PMA-ionomycin. (b) Ratios of HIV-1 unspliced and poly(A) transcripts in resting and total CD4<sup>+</sup> T cells isolated from PWH. The effects of PMA-ionomycin and cell density on HIV-1 latency reversal in (c) resting CD4<sup>+</sup> T cells, (d) total CD4<sup>+</sup> T cells, and (e) the specific ratios of HIV-1 caRNA production in rCD4 compared to tCD4 when plated at a density of 1 million cells/mL, are shown. A given HEAL participant is indicated by circle color. Ratios of HIV-1 caRNA are the ratios of unspliced HIV-1 caRNA to poly(A) HIV-1 mRNA. \*p<0.05, \*\* p<0.01, corrected for multiple comparisons in panels a-d. Panel e was assessed with a Wilcoxon matched-pairs signed rank test, rCD4, resting (CD25-CD69-HLA-DR-) CD4<sup>+</sup> T cells; tCD4, total CD4<sup>+</sup> T cells; NDC, no drug control condition; PMA, PMA 50ng/mL with ionomycin 1µM; Poly-A, polyadenylated HIV-1 caRNA; unspliced, HIV-1 unspliced caRNA; 1m, 1million cells/mL culture media; 5m, 5 million cells/mL culture media.

#### **Materials and Methods**

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

**Study Design and Clinical Cohorts** The Opioids, HIV, and Translation (OPHION) study is a prospective cohort study of participants living with HIV on suppressive antiretroviral therapy recruited from Boston Medical Center which serves one of the largest populations of people living with HIV (PLWH) in Massachusetts, including a disproportionately large number of persons with opioid and substance use disorders. Eligible PLWH were required to currently be on antiretroviral therapy and virologically suppressed (defined as undetectable plasma HIV-1 RNA or <20 copies/ml) for a minimum of 12 months prior to enrollment. Individuals were recruited into 1 of 5 cohorts: (1) active injection opioid use, defined as self-report on injecting opioids at least once per week, (2) Methadone maintenance therapy for at least 3 months, (3) buprenorphine-naloxone therapy for at least 3 months, (4) Prescription oral opioid use for at least 6 months or (5) No opioid use within the past 1 year representing a control cohort. Eligibility into each of the five cohorts was confirmed with a urine toxicology performed at the BMC central laboratory, which includes evaluation for urine drug metabolites including opiates and non-opioid substances as well as an expanded opioid panel which included fentanyl or norfentanyl metabolites. Exclusionary criteria included ongoing immunosuppression and pregnancy; patients who reported injecting non-opioid substances were also not eligible. Once consented and enrolled, each participant underwent blood collection for same day PBMC extraction as well as urine collection for gabapentin and benzodiazepine metabolites. Participants also completed an extensive survey on their current and prior substance use (including alcohol and tobacco use) based the addiction severity index (ASI) (88) and Texas Christian University (TCU) drug screen (89). HIV and other clinical information including ART

treatment history, duration of virologic suppression and comorbidity status including hepatitis C and B were abstracted from the medical record.

The HIV Eradication and Latency (HEAL) Cohort is a longitudinal biorepository study of participants with HIV. Inclusion criteria for HEAL participants in this study were 1) antiretroviral therapy-treated participants with HIV-1 who were virologically suppressed, defined as plasma HIV-1 RNA less than assay (most commonly less than 20 copies/mL, without blips) for >1 year and 2) had sufficient available amounts of cryopreserved PBMC for the proposed analyses. These cohort studies are performed in accordance with the principles of the Declaration of Helsinki. The institutional review boards at Boston Medical Center and Brigham and Women's Hospital (Mass General Brigham Human Research Committee) approved the study protocols. Written informed consent was obtained from all participants. Experimenters were blinded to all clinical data and to OPHION subgroup assignments.

#### **Quantification of HIV-1 persistence markers**

Genomic DNA and total RNA were isolated from approximately 5x10<sup>6</sup> peripheral blood mononuclear cells (PBMC) or total CD4<sup>+</sup> T cells (AllPrep DNA/RNA kit, Qiagen). Total HIV-1 DNA and unspliced cell-associated RNA (caRNA) levels were quantified in triplicate by real-time PCR as previously described, modified to include Taqman Universal Mastermix (DNA) or Taqman Fast Virus 1-Step Mastermix (RNA) (90). HIV-1 quantifications used forward primer 5'-TACTGACGCTCTCGCACC-3', reverse primer 5'-TCTCGACGCAGGACTCG-3', and probe 5' FAM-CTCTCTCCTTCTAGCCTC-MGB 3' (ThermoFisher Scientific). DNA cycling conditions in a total reaction volume of 25μL were 95°C for 15 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. RNA cycling conditions in a total reaction volume of 20μL

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

were 55°C for 15 min, 95°C for 20 sec, followed by 40 cycles of 95°C for 3 sec and 60°C for 30 sec. Approximately 500ng of genomic DNA were assessed per well. The limits of quantification for total HIV-1 DNA and unspliced caRNA were 1 and 3 copies per reaction, respectively. Limits of detection were calculated per timepoint and participant sample, considering the average number of copies detected across triplicate measurements. Cell input numbers were quantified by human genome equivalents of CCR5 DNA using forward primer 5'-ATGATTCCTGGGAGAGACGC-3', reverse primer 5'-AGCCAGGACGGTCACCTT-3', and probe 5' FAM-CTCTCTCTTCTAGCCTC-MGB 3' (ThermoFisher Scientific) as described (90).**Intact proviral DNA assay** HIV-1 DNA from isolated PBMC DNA was measured using the intact proviral DNA assay (IPDA) as previously described with minor modifications (91). Two multiplexed droplet digital PCR assays (Bio-Rad QX200) were performed per sample targeting conserved HIV-1 sequences and, to normalize data, a cell reference gene. Master mixes were prepared using 2X ddPCR Supermix for probes. The HIV-1 specific reaction targeted the *Psi* packaging signal (Forward 5'-CAGGACTCGGCTTGCTGAAG-3'; Reverse 5'-GCACCCATCTCTCTCTCTCTAGC-3'; Probe 5'-TTTTGGCGTACTCACCAGT-3', FAM, MGB) and env (Forward: 5'-AGTGGTGCAGAGAAAAAAGAGC-3'; Reverse: 5'-GTCTGGCCTGTACCGTCAGC-3'; Probe intact: 5'-CCTTGGGTTCTTGGGA-3', VIC/HEX, MGB) sequences with 700 ng DNA per well in duplicate. An additional probe without a fluorophore targeting hypermutated env sequence (Probe hypermutated: 5'-CCTTAGGTTCTTAGGAGC-3', Unlabeled, MGB) was used to exclude defective gene quantification. To estimate the number of cells per reaction and correct

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

for sheared DNA, separate reactions targeting two regions of the RPP30 gene, RPP30-1 (Forward: 5'-GATTTGGACCTGCGAGCG-3'; Reverse: 5'-GCGGCTGTCTCCACAAGT-3'; Probe: 5'-CTGACCTGAAGGCTCT-3', VIC/HEX, MGB) and RPP30-2 (Forward: 5'-GACACAATGTTTGGTACATGGTTAA-3'; Reverse: 5'-CTTTGCTTTGTATGTTGGCAGAAA-3'; Probe: 5'-CCATCTCACCAATCATTCTCCTTC -3', VIC/HEX), with similar nucleotide distance between targets compared to Psi and env were prepared with 70 ng DNA per well. Droplets were generated and subjected to PCR cycle: 95°C for 10 minutes, followed by 45 cycles of 94°C for 30 seconds, 59°C for 1 minute, and ending with 98°C for 10 minutes before holding at 4°C. Data from PCR products were collected and analyzed using QuantaSoft Data Analysis Software. Droplets containing a double positive signal (Psi+/env+) were considered intact, while single positive droplets represented defective provirus containing 5' deletions (Psi-/env+) or 3' deletions/hypermutations (*Psi+/env-*). Relative DNA shearing was calculated using the ratio of single positive RPP30 droplets compared to the double positive population and was used to estimate the number of intact proviruses. The number of diploid cells in each reaction was determined by dividing the copies of RPP30 in half and correcting for the dilution factor for the HIV-1 reaction. Intact, defective, and total HIV-1 DNA were normalized to the number of cells and reported as copies/million PBMC. **Multiply spliced HIV-1 transcripts** To measure the frequency of total CD4<sup>+</sup> T cells with inducible multiply spliced HIV-1 RNA, we performed the TILDA assay, as previously described, with two modifications (56). First, to reduce the 95% CIs around our frequency estimates, we used 36 x 10<sup>6</sup> cells/mL as our first

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

dilution, rather than the 18 x 10<sup>6</sup> cells/mL used in Procopio, et al. Second, to harmonize our PMA-ionomycin concentrations with LRA experiments, we reduced the PMA concentration from its original 100 ng/mL to 50ng/mL in our TILDA assays. The duration of virologic suppression in our HEAL participants was similar to previously reported participants (56). Reference gene quantification Extracted PBMC RNA was used to quantify transcription levels of three host genes, IPO8, TBP, and UBE2D2, typically immediately after the loading of HIV-1 caRNA qPCR plates was complete. IPO8 quantifications used forward primer 5'- CCTTTGTACAACAGAAGGCAC -3', reverse primer 5'- TGCACGTCTCAGGTTTTTGC -3', and probe 5' FAM-TCCGCATAAATCCATTGATTCTGC -MGB 3' (ThermoFisher Scientific); TBP quantifications used forward primer 5'- CAGTGAATCTTGGTTGTAAACTTGA -3', reverse primer 5'- TCGTGGCTCTCTTATCCTCAT -3', and probe 5' FAM-CGCAGCAAACCGCTTGGGATTAT -MGB 3' (ThermoFisher Scientific); and UBE2D2 quantifications used forward primer 5'- GTACTCTTGTCCATCTGTTCTG -3', reverse primer 5'- CCATTCCCGAGCTATTCTGTT -3', and probe 5' VIC-CCGAGCAATCTCAGGCACTAAAGGA -MGB 3' (ThermoFisher Scientific). To generate IPO8 standards, we cloned a fragment corresponding to nucleotides 3636-3707 of IPO8 mRNA (Sequence ID NM 006390.4) into a pCR4-TOPO vector (ThermoFisher Scientific, Cat. No. K458001). To generate TBP standards, a fragment corresponding to nucleotides 649-1037 of TBP mRNA (Sequence ID NM\_003194) was cloned into a pCR4-TOPO vector. To generate UBE2D2 standards, a fragment corresponding to nucleotides 729-1164 of UBE2D2 mRNA (Sequence ID NM 181838.2) was cloned into a pCR4-TOPO vector. Reference gene RNA was

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

synthesized using T3 Megascript Kit (ThermoFisher Cat. No. AM1333 and cleaned (RNease MinElute Cleanup Kit, Qiagen, Cat. No. 74204) before serially diluting across a range of  $10^6$  – 10<sup>3</sup> copies per well. After TBP and UBE2D2 standards were individually validated, TBP (T) and UBE2D2 (U) RNA were diluted separately and aliquoted together as one set of multiplex standards. T and U standards were validated to demonstrate overlap of individual and multiplexed standards curves. The assay was optimized to run all host gene standards and samples on one 96-well reaction plate in a total reaction volume of 20µL using cycling conditions of 55°C for 5 min, 95°C for 20 sec, followed by 40 cycles of 95°C for 3 sec and 56°C for 30 sec. Reference gene standards and samples were run in duplicate. IPO8, TBP, and UBE2D2 RNA copies per million PBMC were calculated by dividing copies per total sample by number of cells per sample, determined by CCR5 quantification, and normalized to 1x10<sup>6</sup> cells. Fold changes were calculated by dividing the RNA copy number obtained per million PBMC for each LRA condition by the 0.2% DMSO control condition's reference gene RNA copies/million PBMC. **HIV-1** latency reversal OPHION and HEAL participant peripheral blood mononuclear cells (PBMC) were isolated from large volume (90 – 180cc) peripheral blood or leukapheresis collections by density centrifugation

OPHION and HEAL participant peripheral blood mononuclear cells (PBMC) were isolated from large volume (90 – 180cc) peripheral blood or leukapheresis collections by density centrifugation and cryopreserved. Cryopreserved PBMC were thawed, pelleted, and transferred to RPMI media supplemented with 10% fetal bovine serum, 2 μM raltegravir, and 2 μM tenofovir (R10 + TDF/RAL) at a concentration of 1x10<sup>6</sup> cells/mL. Cells were rested in a humidified CO<sub>2</sub> incubator at 37°C for three hours (hrs). After 3hrs, cells were counted and assessed for viability. For CD4<sup>+</sup> T cell experiments, PBMC were pelleted, resuspended in EasySep Buffer (StemCell

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

Technologies, cat. no. 20144), and isolated with EasySep Human CD4<sup>+</sup> T Cell Enrichment Kit (StemCell cat. no. 19052) per the manufacturer's instructions. A total of 5x10<sup>6</sup> PBMC, or total CD4<sup>+</sup> T cells, were aliquoted into 5mL of fresh R10 + RAL/TDF in 6-well sterile cell culture plates. Cells were incubated in the presence or absence of the following LRA conditions: 0.2% DMSO, 1:1 αCD3/αCD28 beads (Life Technologies, cat. no. 11131D) to cells with 30 U/mL IL-2 (R&D Systems, cat. no. 202-IL-500), romidepsin 20 nM (Sigma, cat. no. SML1175), panobinostat 30nM (Sigma, cat. no. SML3060), bryostatin-1 1nM (Sigma, cat. no. B7431), AZD5582 100nM (ChemieTek, cat. no. CT-A5582), romidepsin 20 nM plus bryostatin-1 1nM, panobinostat 30nM plus bryostatin-1 1nM 100nM, romidepsin 20 nM plus AZD5582 100nM, panobinostat 30nM plus AZD5582 100nM, and phorbol 12-myristate 13-acetate (PMA) 50ng/mL (Sigma, cat. no. P1585) in combination with ionomycin 1μM (Sigma, cat. no. I9657). To provide a known positive control for subsequent immunology assessments, αCD3/αCD28 beads were used with OPHION samples. Cultures were incubated at 37°C for 24 hours. After 24 hours, cells were prepared for nucleic acid extractions. Comparison of qPCR assays after reactivation CD4<sup>+</sup> T cells were isolated from cryopreserved HEAL participant PBMCs. Total CD4s (tCD4) were isolated using a CD3+CD4+CD8- isolation kit (StemCell cat. no. 17952) and resting CD4s (rCD4) were isolated using a CD3+CD4+CD8-CD25-CD69-HLA-DR- isolation kit (StemCell cat. no. 17962). Cells were pelleted and transferred to RPMI media supplemented with 10% fetal bovine serum, 2 μM raltegravir, and 2 μM tenofovir (R10 + TDF/RAL) at a concentration of  $5\times10^6$  cells/mL. Cells were rested in a humidified CO<sub>2</sub> incubator at 37°C for 3h and then counted and assessed for viability. A total of 5×10<sup>6</sup> tCD4s or rCD4<sup>+</sup> T cells were aliquoted into either

1mL or 5mL of fresh R10 + RAL/TDF in a 24-well sterile cell culture plate or 6-well sterile cell culture plate, respectively. Cells were incubated in either 0.2% DMSO or phorbol 12-myristate 13-acetate (PMA) 50ng/mL (Sigma, cat. no. P1585) in combination with ionomycin 1µM (Sigma, cat. no. 19657). Cultures were incubated at 37°C for 24 hours. After 24 hours, cells were prepared for nucleic acid extractions. RNA was eluted in a total volume of 65uL and DNA eluted in a volume of 100uL. For HIV-1 unspliced caRNA quantifications, 10uL of RNA were assessed in triplicate using primers and probe that bind the HIV-1 gag region (90). To calculate copies of HIV-1 caRNA per million cells, copy numbers were averaged and cell counts normalized to a CCR5 DNA reference. For polyadenylated HIV-1 mRNA quantifications, 10uL (approximately 1 million cell equivalents) of RNA were run in triplicate using primers and probe targeting the nef to poly-A region of HIV-1 mRNA as previously described (28). Our HIV-1 unspliced and poly(A) caRNA amplifications are both one-step qPCR assays that use an HIV-specific primer to synthesize cDNA. Standards were generated as previously described (92). For poly(A) HIV-1 mRNA quantifications, copies per million cell equivalents were calculated by initial cell count prior to reactivation. Both assays used Taqman Fast Virus 1-Step Mastermix in a total reaction volume of 20µL and cycling conditions of 55°C for 15 min, 95°C for 20 sec, followed by 40 cycles of 95°C for 3 sec and 60°C for 30 sec. Fold-change was calculated by dividing copies per million cells in the PMAi condition by copies per million cells in the 0.2% DMSO no drug control condition for each sample.

## **Activation Induced Marker (AIM) assay**

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

AIM assays were performed as previously described (54). Briefly, cryopreserved PBMC were thawed, washed, resuspended in R10, and rested for 3 hours at 37°C. Following the 3-hour rest

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

interval, the appropriate number of cells were transferred to a 48-well plate and subsequently treated with CD40 blocking antibody (Miltenyi Biotec, cat. no. 130-094-133) for a final concentration of 0.5 ug/mL for 15 minutes at 37°C. Cells were incubated in the presence or absence of our 10-LRA panel, as previously described. After an 18hr incubation, cells were harvested and stained for 50 minutes at 4°C with the surface staining monoclonal antibodies (mAb); (PD-L1-PE/Cy7 (Biolegend, cat. no. 329717), CD40L-PE (BD Biosciences [BD], cat. no. 561720), OX40-APC (BD cat. no. 563473), CD69-BV650 (Biolegend cat. no. 310933), CD3-BV605 (Biolegend cat. no. 317322), CD4-BV421 (BD cat. no. 562424), CD8-PerCp-Cy5.5 (BD cat. no. 560662), CD25- BUV395 (BD cat. no. 564034) and LIVE/DEAD Near-IR stain (ThermoFisher cat. no. L34975), washed, fixed and permeabilized (BD cytofix fixation buffer, cat. no. 554655), and then stained for 30 minutes at 4°C with intracellular mAb Acetyl-histone H3-Alexa Fluor 488 (Cell Signaling Technology, cat. no. 9683S) in 1x perm/wash buffer (BD, cat. no. 554723). The cells were washed and fixed (BD cytofix fixation buffer, cat. no. 554655) prior to flow cytometry analysis. **Intracellular cytokine staining** Cryopreserved PBMC were thawed, washed, resuspended in RPMI + 10% FBS (R10), and rested for 3 hours at 37°C. Following the 3-hour rest interval, the appropriate number of cells were transferred to a 48-well plate and incubated for 2 hrs with our panel of 10 LRA. Following this 2-hour incubation period, GolgiPlug (BD, cat. no. 555029) and GolgiStop (BD, cat. no. 554724) were added to each condition at a concentration of 1:1000 and 6:10000 respectively, then incubated at 37°C for an additional 16 hrs. Cells were harvested, pelleted, resuspended, stained for 20 minutes at 4°C with surface staining mAb (CD3-BV605, CD4-BV421, CD8-

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

PerCp-Cv5.5 and LIVE/DEAD Near-IR stain), fixed and permeabilized as described above, and then stained for 30 minutes at 4°C with the intracellular mAb TNF-α- PE/Dazzle-594 (Biolegend cat. no. 502946), IL-2- PE/Cy7 (BD cat. no. 560707) and IFN-y- BV510 (Biolegend cat. no. 502544). PBMC were washed and fixed in (BD cytofix fixation buffer, cat. no. 554655) prior to flow cytometry analysis, as described above. Flow cytometry Cells were acquired on a BD LSRFortessa using FACSDiva. Analysis was performed using Flow Jo software versions 10.6.2 (Treestar, Versions 10 for Mac). Representative gating strategies can be found in the supplemental figures. **Statistical analysis** Statistical analyses were performed using GraphPad Prism 9 for macOS. Means, medians, 95% confidence intervals, and standard errors of the mean were calculated. The pre-specified primary outcome of OPHION was a comparison of log<sub>10</sub> PBMC HIV-1 caRNA levels between participants who use and do not use opioids. The pre-specified outcome for OPHION latency reversal experiments was the difference in HIV-1 caRNA levels between LRA treatment groups and across opioid use groups. To assess for changes in HIV-1 caRNA, we performed Kruskal-Wallis testing of all participants together for each of the LRAs with Dunn's multiple comparison test, comparing the mean ranks of LRA conditions. An identical approach was taken with a series of exploratory analyses with OPHION participant samples that assessed histone acetylation, surface activation, and intracellular cytokine production, and with the exploratory

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

statistical analyses performed on experiments with HEAL participant samples, unless otherwise specifically stated in the text. Acknowledgements This work is supported by the National Institutes of Health (NIH) R61 DA047038 (NL and AT) and R33 DA047038 (AT) and was facilitated by the Providence/Boston Center for AIDS Research (P30AI042853) and the Harvard University Center for AIDS Research (P30AI060354). The project described was further supported by Clinical Translational Science Award 1UL1TR002541-01 to Harvard University and Brigham and Women's Hospital from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. **Author contributions:** Conceptualization: AA, JT, KC, NL, AT Methodology: AA, JT, KC, NL, AT Investigation: TL, JB, AA, AO, KC, HC, HJ, KC Visualization: TL, JB, AA, AO, KC, AT Funding acquisition: NL, AT Project administration: AA, SR, NL, AT Supervision: AA, NL, AT Writing – original draft: TL, JB, AA, AO, NL, AT Writing – review & editing: TL, AA, NL, AT

**Declaration of interests:** NL is now an employee of Moderna, Inc. AT has received remuneration from EBSCO Dynamed. Additional authors declare that they have no competing interests.

## References

851

- 1. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a
- pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proceedings of
- the National Academy of Sciences of the United States of America. 1998;95(15):8869-73.
- Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid
- seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature.
- 857 2014;512(7512):74-7.
- Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery
- of replication-competent HIV despite prolonged suppression of plasma viremia. Science (New
- 860 York, NY. 1997;278(5341):1291-5.
- Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an
- inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the
- National Academy of Sciences of the United States of America. 1997;94(24):13193-7.
- 5. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent
- infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in
- patients on effective combination therapy. Nature medicine. 1999;5(5):512-7.
- 6. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term
- follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.
- 869 Nature medicine. 2003;9(6):727-8.
- 7. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV
- reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature
- medicine. 2009;15(8):893-900.

- 873 8. Mullins JI, Frenkel LM. Clonal Expansion of Human Immunodeficiency Virus-Infected
- 874 Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy. The
- Journal of infectious diseases. 2017;215(suppl\_3):S119-S27.
- 9. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, et al.
- International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature
- 878 medicine. 2016.
- 879 10. Ferrari G, Pollara J, Tomaras GD, Haynes BF. Humoral and Innate Antiviral Immunity as
- Tools to Clear Persistent HIV Infection. The Journal of infectious diseases.
- 881 2017;215(suppl\_3):S152-S9.
- 882 11. Riley JL, Montaner LJ. Cell-Mediated Immunity to Target the Persistent Human
- Immunodeficiency Virus Reservoir. The Journal of infectious diseases. 2017;215(suppl\_3):S160-
- 884 **S**71.
- McMahon DK, Zheng L, Cyktor JC, Aga E, Macatangay BJ, Godfrey C, et al. A Phase
- 886 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on
- 887 Suppressive Antiretroviral Therapy. The Journal of infectious diseases. 2021;224(4):648-56.
- 888 13. Scully EP, Aga E, Tsibris A, Archin N, Starr K, Ma Q, et al. Impact of Tamoxifen on
- Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral
- Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clin Infect Dis.
- 891 2022;75(8):1389-96.
- 692 14. Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias MJ, Martin ME, Barbas C, et
- al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.
- 894 AIDS (London, England). 2016;30(9):1385-92.

- 895 15. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV-1
- expression within resting CD4+ T cells after multiple doses of vorinostat. The Journal of
- infectious diseases. 2014;210(5):728-35.
- 898 16. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al.
- Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature.
- 900 2012;487(7408):482-5.
- 901 17. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation
- of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive
- antiretroviral therapy. PLoS pathogens. 2014;10(10):e1004473.
- 904 18. Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The
- Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS pathogens.
- 906 2015;11(9):e1005142.
- 907 19. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al.
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected
- 909 patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. The lancet
- 910 HIV. 2014;1(1):e13-21.
- 911 20. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valproic acid
- in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs:
- 913 results from a multicentre randomized clinical study. HIV medicine, 2012;13(5):291-6.
- 914 21. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, et al.
- 915 Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS
- 916 (London, England). 2008;22(10):1125-9.

- 22. Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, et al. Interval dosing
- with the HDAC inhibitor vorinostat effectively reverses HIV latency. The Journal of clinical
- 919 investigation. 2017;127(8):3126-35.
- 920 23. Yukl SA, Kaiser P, Kim P, Telwatte S, Joshi SK, Vu M, et al. HIV latency in isolated
- patient CD4(+) T cells may be due to blocks in HIV transcriptional elongation, completion, and
- 922 splicing. Science translational medicine. 2018;10(430).
- 923 24. Moron-Lopez S, Kim P, Sogaard OS, Tolstrup M, Wong JK, Yukl SA. Characterization
- of the HIV-1 transcription profile after romidepsin administration in ART-suppressed
- 925 individuals. AIDS (London, England). 2019;33(3):425-31.
- 25. Zerbato JM, Khoury G, Zhao W, Gartner MJ, Pascoe RD, Rhodes A, et al. Multiply
- 927 spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following
- reversal of HIV latency. EBioMedicine. 2021;65:103241.
- 929 26. Martin HA, Kadiyala GN, Telwatte S, Wedrychowski A, Chen TH, Moron-Lopez S, et
- al. New Assay Reveals Vast Excess of Defective over Intact HIV-1 Transcripts in Antiretroviral
- Therapy-Suppressed Individuals. Journal of virology. 2022;96(24):e0160522.
- 932 27. Rodari A, Darcis G, Van Lint CM. The Current Status of Latency Reversing Agents for
- 933 HIV-1 Remission. Annu Rev Virol. 2021;8(1):491-514.
- 934 28. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, et al. Ex vivo
- analysis identifies effective HIV-1 latency-reversing drug combinations. The Journal of clinical
- 936 investigation. 2015;125(5):1901-12.
- 937 29. Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, et al. BIRC2/cIAP1 Is
- a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to
- 939 Promote Reversal of Viral Latency. Cell host & microbe. 2015;18(3):345-53.

- 940 30. Grau-Exposito J, Luque-Ballesteros L, Navarro J, Curran A, Burgos J, Ribera E, et al.
- Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T
- 942 subpopulations. PLoS pathogens. 2019;15(8):e1007991.
- 943 31. Pardons M, Fromentin R, Pagliuzza A, Routy JP, Chomont N. Latency-Reversing Agents
- Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on
- 945 Antiretroviral Therapy. Cell Rep. 2019;29(9):2783-95 e5.
- Dai W, Wu F, McMyn N, Song B, Walker-Sperling VE, Varriale J, et al. Genome-wide
- 947 CRISPR screens identify combinations of candidate latency reversing agents for targeting the
- latent HIV-1 reservoir. Science translational medicine. 2022;14(667):eabh3351.
- 949 33. Gupta V, Dixit NM. Trade-off between synergy and efficacy in combinations of HIV-1
- latency-reversing agents. PLoS computational biology. 2018;14(2):e1006004.
- 951 34. Kao SY, Calman AF, Luciw PA, Peterlin BM. Anti-termination of transcription within
- the long terminal repeat of HIV-1 by tat gene product. Nature. 1987;330(6147):489-93.
- 953 35. Adams M, Sharmeen L, Kimpton J, Romeo JM, Garcia JV, Peterlin BM, et al. Cellular
- latency in human immunodeficiency virus-infected individuals with high CD4 levels can be
- 955 detected by the presence of promoter-proximal transcripts. Proceedings of the National Academy
- of Sciences of the United States of America. 1994;91(9):3862-6.
- 957 36. Lassen KG, Bailey JR, Siliciano RF. Analysis of human immunodeficiency virus type 1
- 958 transcriptional elongation in resting CD4+ T cells in vivo. Journal of virology.
- 959 2004;78(17):9105-14.
- 960 37. Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, et al.
- Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of
- inflammation or activation. PLoS pathogens. 2017;13(4):e1006285.

- 963 38. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative
- analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS pathogens.
- 965 2013;9(2):e1003174.
- 966 39. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, et al. Cell-based measures of
- viral persistence are associated with immune activation and programmed cell death protein 1
- 968 (PD-1)-expressing CD4+ T cells. The Journal of infectious diseases. 2013;208(1):50-6.
- 969 40. Telwatte S, Lee S, Somsouk M, Hatano H, Baker C, Kaiser P, et al. Gut and blood differ
- in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the
- mechanisms that govern HIV latency. PLoS pathogens. 2018;14(11):e1007357.
- 972 41. Edelman EJ, Gordon K, Becker WC, Goulet JL, Skanderson M, Gaither JR, et al. Receipt
- of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med. 2013;28(1):82-
- 974 90.
- 975 42. Reddon H, Milloy MJ, Simo A, Montaner J, Wood E, Kerr T. Methadone maintenance
- 976 therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit
- 977 drug users. AIDS Behav. 2014;18(4):740-6.
- 978 43. Tavitian-Exley I, Vickerman P, Bastos FI, Boily MC. Influence of different drugs on HIV
- 979 risk in people who inject: systematic review and meta-analysis. Addiction. 2015;110(4):572-84.
- 980 44. Borner C, Kraus J, Bedini A, Schraven B, Hollt V. T-cell receptor/CD28-mediated
- activation of human T lymphocytes induces expression of functional mu-opioid receptors. Mol
- 982 Pharmacol. 2008;74(2):496-504.
- 983 45. Borner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, et al. Mechanisms
- of opioid-mediated inhibition of human T cell receptor signaling. J Immunol. 2009;183(2):882-9.

- 985 46. Mbonye U, Karn J. Transcriptional control of HIV latency: Cellular signaling pathways,
- epigenetics, happenstance and the hope for a cure. Virology. 2014.
- 987 47. Basukala B, Rossi S, Bendiks S, Gnatienko N, Patts G, Krupitsky E, et al. Virally
- Suppressed People Living with HIV Who Use Opioids Have Diminished Latency Reversal.
- 989 Viruses. 2023;15(2).
- 990 48. Telwatte S, Kim P, Chen TH, Milush JM, Somsouk M, Deeks SG, et al. Mechanistic
- 991 differences underlying HIV latency in the gut and blood contribute to differential responses to
- latency-reversing agents. AIDS (London, England). 2020;34(14):2013-24.
- 993 49. Martin AR, Pollack RA, Capoferri A, Ambinder RF, Durand CM, Siliciano RF.
- Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-
- associated toxicity. The Journal of clinical investigation. 2017;127(2):651-6.
- 996 50. Yang X, Wang Y, Lu P, Shen Y, Zhao X, Zhu Y, et al. PEBP1 suppresses HIV
- transcription and induces latency by inactivating MAPK/NF-kappaB signaling. EMBO Rep.
- 998 2020;21(11):e49305.
- 999 51. Carlin E, Greer B, Lowman K, Duverger A, Wagner F, Moylan D, et al. Extensive
- proteomic and transcriptomic changes quench the TCR/CD3 activation signal of latently HIV-1
- infected T cells. PLoS pathogens. 2021;17(1):e1008748.
- 1002 52. Palermo E, Acchioni C, Di Carlo D, Zevini A, Muscolini M, Ferrari M, et al. Activation
- of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic
- 1004 Regulators. Journal of virology. 2019;93(21).
- 1005 53. Nixon CC, Mavigner M, Sampey GC, Brooks AD, Spagnuolo RA, Irlbeck DM, et al.
- Systemic HIV and SIV latency reversal via non-canonical NF-kappaB signalling in vivo. Nature.
- 1007 2020;578(7793):160-5.

- 1008 54. Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, et al. Comparative
- analysis of activation induced marker (AIM) assays for sensitive identification of antigen-
- specific CD4 T cells. PLoS ONE. 2017;12(10):e0186998.
- 1011 55. Ceriani C, Streeter GS, Lemu KJ, James KS, Ghofrani S, Allard B, et al. Defining stable
- reference genes in HIV latency reversal experiments. Journal of virology. 2021;95(11).
- 1013 56. Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, et al. A Novel
- Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.
- 1015 EBioMedicine. 2015;2(8):874-83.
- 1016 57. Mehandru S, Deren S, Kang SY, Banfield A, Garg A, Garmon D, et al. Behavioural,
- Mucosal and Systemic Immune Parameters in HIV-infected and Uninfected Injection Drug
- 1018 Users. J Addict Res Ther. 2015;6(4):1-8.
- Deren S, Cleland CM, Lee H, Mehandru S, Markowitz M. Brief Report: The Relationship
- Between Injection Drug Use Risk Behaviors and Markers of Immune Activation. Journal of
- acquired immune deficiency syndromes (1999). 2017;75(1):e8-e12.
- 1022 59. Khoury G, Fromentin R, Solomon A, Hartogensis W, Killian M, Hoh R, et al. Human
- 1023 Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node
- Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive
- Antiretroviral Therapy. The Journal of infectious diseases. 2017;215(6):911-9.
- 1026 60. Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs:
- alliance against an HIV cure. Current opinion in HIV and AIDS. 2016;11(2):234-41.
- 1028 61. Ruggiero A, De Spiegelaere W, Cozzi-Lepri A, Kiselinova M, Pollakis G, Beloukas A, et
- al. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral

- Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.
- 1031 EBioMedicine. 2015;2(9):1153-9.
- 1032 62. Cockerham LR, Siliciano JD, Sinclair E, O'Doherty U, Palmer S, Yukl SA, et al. CD4+
- and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. PLoS ONE.
- 1034 2014;9(10):e110731.
- 1035 63. Kirk GD, Astemborski J, Mehta SH, Ritter KD, Laird GM, Bordi R, et al. Nonstructured
- 1036 Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir
- Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. The Journal of
- infectious diseases. 2021;223(11):1905-13.
- 1039 64. Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, et al.
- Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat
- 1041 Commun. 2019;10(1):3193.
- 1042 65. Falcinelli SD, Peterson JJ, Turner AW, Irlbeck D, Read J, Raines SL, et al. Combined
- 1043 noncanonical NF-kappaB agonism and targeted BET bromodomain inhibition reverse HIV
- latency ex vivo. The Journal of clinical investigation. 2022;132(8).
- 1045 66. Li D, Dewey MG, Wang L, Falcinelli SD, Wong LM, Tang Y, et al. Crotonylation
- sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52. iScience.
- 1047 2022;25(1):103649.
- 1048 67. Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, et al. Histone
- 1049 Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and
- 1050 Pharmacological Actionability. Genes (Basel). 2020;11(5).

- 1051 68. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of
- latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase
- inhibitors. AIDS (London, England). 2009;23(14):1799-806.
- 1054 69. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. Ex Vivo Bioactivity
- and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells
- from Aviremic Patients. Antimicrobial agents and chemotherapy. 2015;59(10):5984-91.
- 1057 70. Banga R, Procopio FA, Cavassini M, Perreau M. In Vitro Reactivation of Replication-
- 1058 Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors. Journal of virology.
- 1059 2016;90(4):1858-71.
- Tsai P, Wu G, Baker CE, Thayer WO, Spagnuolo RA, Sanchez R, et al. In vivo analysis
- of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV
- infection. Retrovirology. 2016;13(1):36.
- 1063 72. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. Histone deacetylase inhibitors
- 1064 (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory
- complex also activate HIV transcription. The Journal of biological chemistry.
- 1066 2013;288(20):14400-7.
- 1067 73. Halsall JA, Turan N, Wiersma M, Turner BM. Cells adapt to the epigenomic disruption
- caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated
- transcriptional response. Epigenetics Chromatin. 2015;8:29.
- 1070 74. Chen FX, Smith ER, Shilatifard A. Born to run: control of transcription elongation by
- 1071 RNA polymerase II. Nat Rev Mol Cell Biol. 2018;19(7):464-78.

- 1072 75. Marsden MD, Loy BA, Wu X, Ramirez CM, Schrier AJ, Murray D, et al. In vivo
- activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and
- "kill" in strategy for virus eradication. PLoS pathogens. 2017;13(9):e1006575.
- 1075 76. Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, et al. Synthetic
- 1076 Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal. Antimicrobial agents
- and chemotherapy. 2018;62(11).
- 1078 77. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone
- Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on
- Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing. PLoS
- pathogens. 2014;10(4):e1004071.
- Walker-Sperling VE, Pohlmeyer CW, Tarwater PM, Blankson JN. The Effect of Latency
- 1083 Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for
- Human Immunodeficiency Virus Eradication. EBioMedicine. 2016;8:217-29.
- 1085 79. Bouchat S, Delacourt N, Kula A, Darcis G, Van Driessche B, Corazza F, et al. Sequential
- treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO Mol
- 1087 Med. 2016;8(2):117-38.
- 1088 80. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, et al. An In-Depth
- 1089 Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1
- Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral
- 1091 Gene Expression. PLoS pathogens. 2015;11(7):e1005063.
- 1092 81. Bui JK, Mellors JW, Cillo AR. HIV-1 Virion Production from Single Inducible
- 1093 Proviruses following T-Cell Activation Ex Vivo. Journal of virology. 2016;90(3):1673-6.

- Wedrychowski A, Martin HA, Li Y, Telwatte S, Kadiyala GN, Melberg M, et al.
- 1095 Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control. Journal
- 1096 of virology. 2023;97(1):e0125422.
- 1097 83. Moron-Lopez S, Telwatte S, Sarabia I, Battivelli E, Montano M, Macedo AB, et al.
- Human splice factors contribute to latent HIV infection in primary cell models and blood CD4+
- T cells from ART-treated individuals. PLoS pathogens. 2020;16(11):e1009060.
- 1100 84. Mota TM, McCann CD, Danesh A, Huang SH, Magat DB, Ren Y, et al. Integrated
- Assessment of Viral Transcription, Antigen Presentation, and CD8(+) T Cell Function Reveals
- Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency
- 1103 Reversal. Journal of virology. 2020;94(9).
- Walker-Sperling VE, Cohen VJ, Tarwater PM, Blankson JN. Reactivation Kinetics of
- HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific
- 1106 CD8+ T Cells. Journal of virology. 2015;89(18):9631-8.
- Kula A, Delacourt N, Bouchat S, Darcis G, Avettand-Fenoel V, Verdikt R, et al.
- Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined
- Disulfiram+Romidepsin Treatments. Journal of acquired immune deficiency syndromes (1999).
- 1110 2019;80(5):605-13.
- 1111 87. Mbonye U, Leskov K, Shukla M, Valadkhan S, Karn J. Biogenesis of P-TEFb in CD4+ T
- cells to reverse HIV latency is mediated by protein kinase C (PKC)-independent signaling
- pathways. PLoS pathogens. 2021;17(9):e1009581.
- 1114 88. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The Fifth
- Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199-213.

89. Institute of Behavioral Research. Texas Christian University Drug Screen 5. Fort Worth: 1116 Texas Christian University, Institute of Behavioral Research (2020) https://ibr.tcu.edu/forms/tcu-1117 drug-screen/[ 1118 1119 90. Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, et al. A universal 1120 real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nature protocols. 2008;3(7):1240-8. 1121 1122 91. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A 1123 quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature. 2019;566(7742):120-5. 1124 92. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches 1125 distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature 1126 1127 medicine. 2014;20(4):425-9. 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138

## **Supplementary Figures Legends**

1139

1140

1141

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

**Supplementary Figure 1.** Substance use in the OPHION cohort. We assessed substance use by (a) clinical urine toxicology testing and (b) self-reported substance use questionnaires. Substance use results are separated by cohort groups by participant ID. Red squares indicate the presence of that substance in a urine sample; unavailable data were marked with "X" in a gray box. An expanded opiate panel was performed to assess for the presence of different opiate formulations. Color squares in panel b reflect any reported use by participants in the last 30 days. The numbers inside a given box indicate the number of days used this substance was reported to be used in the last 30 days. Gradient of color from blue to red indicate increasing report of use whereas white indicates no use. Concomitant use of alcohol, tobacco, marijuana, and gabapentin in the OPHION cohort was common. \*all fentanyl measures were confirmed by follow-on quantification. Participants in the buprenorphine and methadone groups reported daily use of the respective medication in the 30 days prior, whereas participants taking opioids for chronic pain took opioids for 27-30 days in the 30 days preceding their enrollment in OPHION. 75% (N=3/4) of active injection users had urine toxicology screens positive for cocaine corresponding with self-report; all three reported smoking cocaine in the prior 30 days to specimen collection. One of twelve participants in the methadone use group and 2/12 in the non-opiate use group also has urine toxicology screens positive for cocaine. All active injection opioid users reported using multiple drugs on the same day in the last 30 days compared to 1/12 participants in non-opioid use group and 10/20 participants in methadone, buprenorphine and prescription opiate use groups combined. N=3/4 active injection opioid users reported smoking marijuana in the last 30 days. 6 and 8 participants about the 12 participants in opioid use groups had urine toxicology screens positive for benzodiazepines and gabapentin; all but 1 in both cases reported that this

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

substance was prescribed. No participant had urine toxicology screens positive for amphetamines or barbiturates. All participants injecting opioids used tobacco in the preceding 30 days and, overall, 23 of 36 OPHION participants used tobacco within the month prior to their blood collection. 25% (N=6/24) of opioid use participants consumed alcohol in last 30 days compared to 58% (7/12) in the control group. **Supplementary Figure 2.** HIV-1 LRA boosting response in the OPHION cohort by subgroup analysis. (a) HIV-1 fold-increase in unspliced RNA transcription plotted as a function of selfreported Hispanic (dark purple circles) or non-Hispanic (light blue circles) ethnicity. (b) Opioiduse subgroup analysis highlighting LRA response to αCD3/αCD28 beads from Main Fig 1a, as a function of opioid use subgroup. Means and SEM are shown. Dotted horizontal line denotes a fold-change of 1. \*\* p<0.01 for LRA combinations, corrected for multiple comparisons. αCD3/αCD28, anti-CD3 anti-CD28 superparamagnetic beads; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM. **Supplementary Figure 3.** Flow cytometry gating strategies. Representative intracellular cytokine staining plots for (a) control and (b) αCD3/αCD28 bead-exposed PBMC are shown. (c) Gating strategy for the three AIM assays. A representative sample exposed to TCR agonism is shown. **Supplementary Figure 4.** LRA-induced immune activation as a function of opioid use. Results obtained with the (a) OX40/PD-L1, (b) OX40/CD25, and (c) CD69/CD40L AIM assays are

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

reported for all ten conditions in the LRA panel, where samples from participants with (blue circles) and without (yellow circles) opioid use are shown. Data are represented as means  $\pm 95\%$ CIs. For the OX40/PL-L1 assay, the highest measured levels in OX40/PDL1 assay with bryostatin 1nM, R+B, and P+B are the same non-opioid-using participant. (d) Individual data points for CD69<sup>+</sup> live total CD4+ T cells, as a function of opioid use. (e) Comparative hierarchies of intracellular cytokine production in CD4<sup>+</sup> and CD8<sup>+</sup> T cells exposed to TCR agonism ( $\alpha$ CD3/ $\alpha$ CD28 beads). Data displayed in these panels are identical to the data values shown in Main Fig. 3. \*p<0.05, \*\* p<0.01, \*\*\*\* p<0.0001, corrected for multiple comparisons. TNF, tumor necrosis factor alpha; IFN, interferon gamma; IL-2, interleukin-2; CD4, CD4<sup>+</sup> T cells; CD8, CD8<sup>+</sup> T cells. **Supplementary Figure 5.** Histone acetylation effects during LRA boosting, as a function of opioid use. Using the same data displayed in Main Fig. 4, here we show individual data points, labelled as samples from participants with (blue circles) and without (yellow circles) opioid use. (a) The proportion of live total CD4<sup>+</sup> T cells with acetylated histone H3, assessed by flow cytometry, (b) Mean fluorescence intensity (MFI) of acetylated histone H3 per live total CD4<sup>+</sup> T cells. **Supplementary Figure 6.** The effects of LRA boosting on human reference gene transcription. Using leukapheresis samples from HEAL participants (n=10), we assessed and compared foldchanges in transcription of three host genes: (a) IPO8, (b) TBP, and (c) UBE2D2. Reference gene multiplexing was validated for (d) TBP and (e) UBE2D2 quantifications. The rationale to study these three reference genes is as follows. IPO8 transcription is used as an internal control

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

by the AIDS Clinical Trials Group's Virology Specialty Laboratories to measure RNA integrity in a dichotomous way. IPO8 Ct values >27 are used to suggest degradation of cellular samples in storage, and samples with IPO8 Ct >27 do not report HIV-1 RNA values. Recent work by Nancie Archin's group at the UNC HIC Cure Center identified TBP and UBE2D2 as two of the more stable host genes during their LRA exposures, which included PMA, AZD5582, and HDACi, among a panel of eight LRA. **Supplementary Figure 7.** The effects of LRA boosting on human reference gene transcription. Using leukapheresis samples from HEAL participants (n=9), we assessed and compared fold changes in transcription of three host genes: (a) IPO8, (b) TBP, and (c) UBE2D2. Reference gene multiplexing was validated for (d) TBP and (e) UBE2D2 quantifications. The rationale to study these three reference genes is as follows. IPO8 transcription is used as an internal control by the AIDS Clinical Trials Group's Virology Specialty Laboratories to measure RNA integrity in a dichotomous way. IPO8 Ct values >27 are used to suggest degradation of cellular samples in storage, and samples with IPO8 Ct >27 do not report HIV-1 RNA values. Recent work by Nancie Archin at the UNC HIV Cure Center identified TBP and UBE2D2 as two of the more stable host genes during LRA exposures, which included PMA, AZD5582, and HDACi, among a panel of eight LRA. Supplementary Figure 8. Variance in LRA response. (a) Magnitude of HIV-1 caRNA transcription fold-changes in biological replicate LRA experiments performed with HEAL leukapheresis samples, using the same data as shown in Main Fig 5a-c, (b) Box and whiskers plot displaying the data of Fig. 5g as the mean (solid black horizontal line), inter-quartile range

(25<sup>th</sup> – 75<sup>th</sup> percentiles denoted as the borders of the vertical rectangle), and 5<sup>th</sup>-95<sup>th</sup> percentiles (whiskers, error bars). Values below and above the whiskers are shown as individual data points. PMA-iono, PMA with ionomycin; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM.

Supplementary Tables

Supplementary Table 1 – Breakdown of OPHION cohort into opioid use subgroups

Supplementary Table 2 – HEAL Participant Characteristics




Figure 1







Figure 2







b.

a.

Figure 5




Figure 6